Harrysson S - Search Results

Year	Number of Results
2020	3
2021	4
2022	2
2023	3
2024	1
2025	1

1

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Lewis KL, Jakobsen LH, Villa D, Smedby KE, Savage KJ, Eyre TA, Cwynarski K, Bishton MJ, Fox CP, Hawkes EA, Maurer MJ, El-Galaly TC, Cheah CY; International CNS Prophylaxis Study Group. Lewis KL, et al. J Clin Oncol. 2023 Dec 10;41(35):5376-5387. doi: 10.1200/JCO.23.00365. Epub 2023 Oct 5. J Clin Oncol. 2023. PMID: 37797284

2

Myocardial infarction in diffuse large B-cell lymphoma patients - a population-based matched cohort study.

Ekberg S, Harrysson S, Jernberg T, Szummer K, Andersson PO, Jerkeman M, Smedby KE, Eloranta S. Ekberg S, et al. Among authors: harrysson s. J Intern Med. 2021 Nov;290(5):1048-1060. doi: 10.1111/joim.13303. Epub 2021 May 18. J Intern Med. 2021. PMID: 34003533 Free article.

3

ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study.

Rodriguez-Wallberg KA, Nilsson HP, Bergh J, Malmros J, Ljungman P, Foukakis T, Stragliotto CL, Friman EI, Linderholm B, Valachis A, Andersson A, Harrysson S, Vennström L, Frisk P, Mörse H, Eloranta S. Rodriguez-Wallberg KA, et al. Among authors: harrysson s. BMJ Open. 2023 Dec 9;13(12):e078023. doi: 10.1136/bmjopen-2023-078023. BMJ Open. 2023. PMID: 38070906 Free PMC article.

4

Patient trajectories after diagnosis of diffuse large B-cell lymphoma-a multistate modelling approach to estimate the chance of lasting remission.

Ekberg S, Crowther M, Harrysson S, Jerkeman M, E Smedby K, Eloranta S. Ekberg S, et al. Among authors: harrysson s. Br J Cancer. 2022 Nov;127(9):1642-1649. doi: 10.1038/s41416-022-01931-2. Epub 2022 Aug 23. Br J Cancer. 2022. PMID: 35999271 Free PMC article.

5

Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.

Harrysson S, Eloranta S, Ekberg S, Enblad G, El-Galaly TC, Sander B, Sonnevi K, Andersson PO, Jerkeman M, Smedby KE. Harrysson S, et al. Br J Haematol. 2022 Jul;198(2):267-277. doi: 10.1111/bjh.18197. Epub 2022 Apr 25. Br J Haematol. 2022. PMID: 35468219 Free PMC article.

6

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden.

Harrysson S, Eloranta S, Ekberg S, Enblad G, Jerkeman M, Wahlin BE, Andersson PO, Smedby KE. Harrysson S, et al. Blood Cancer J. 2021 Jan 7;11(1):9. doi: 10.1038/s41408-020-00403-1. Blood Cancer J. 2021. PMID: 33414443 Free PMC article.

7

Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study.

Sonnevi K, Wästerlid T, Melén CM, Harrysson S, Smedby KE, Wahlin BE. Sonnevi K, et al. Among authors: harrysson s. Br J Haematol. 2021 Jan;192(1):75-81. doi: 10.1111/bjh.16737. Epub 2020 May 12. Br J Haematol. 2021. PMID: 32400004

8

Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience.

Sonnevi K, Ljungqvist M, Jóelsson JK, Harrysson S, Wästerlid T, Bernell P, Wahlin BE. Sonnevi K, et al. Among authors: harrysson s. EJHaem. 2021 Sep 28;2(4):774-784. doi: 10.1002/jha2.296. eCollection 2021 Nov. EJHaem. 2021. PMID: 35845206 Free PMC article.

9

Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy.

Harrysson S, Eloranta S, Ekberg S, Enblad G, Andersson PO, Sonnevi K, Ljungqvist M, Sander B, Jerkeman M, Smedby KE. Harrysson S, et al. Leuk Lymphoma. 2024 Apr;65(4):534-537. doi: 10.1080/10428194.2023.2296361. Epub 2023 Dec 22. Leuk Lymphoma. 2024. PMID: 38134325 No abstract available.

10

Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma.

Wästerlid T, Harrysson S, Andersson TM, Ekberg S, Enblad G, Andersson PO, Jerkeman M, Eloranta S, Smedby KE. Wästerlid T, et al. Among authors: harrysson s. Am J Hematol. 2020 Jul;95(7):740-748. doi: 10.1002/ajh.25789. Epub 2020 Apr 3. Am J Hematol. 2020. PMID: 32180274 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year